NCT01979523 2026-03-19
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT01989585 2026-03-19
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03190915 2026-03-19
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02642042 2026-03-04
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02015117 2025-10-23
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02079740 2025-09-30
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02070549 2025-02-13
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed